Adjuvant phage therapy in periprosthetic joint infection: comparative analysis of medium-term treatment results
TL;DR
Adjuvant phage therapy combined with antibiotic therapy is an effective treatment modality for periprosthetic hip joint infection caused by multidrug-resistant pathogens and may significantly reduce the recurrence rate of periprosthetic infection and thereby improve clinical outcomes.
Abstract
Introduction Periprosthetic joint infection (PJI) is one of the major complications following primary and revision total hip arthroplasty, accounting for 15–25 % of revision procedures. PJI caused by multidrug-resistant microorganisms is associated with a higher risk of recurrence and severe consequences, including loss of limb function and amputation. The growing prevalence of antimicrobial resistance, particularly among staphylococci and Gram-negative bacteria, further complicates the PJI treatment. Purpose To conduct a comparative analysis of the mid-term results of adjuvant phage therapy in combination with standard therapy in patients with periprosthetic hip joint infection caused by multidrug-resistant microorganisms. Materials and Methods The study was designed as a non-randomized, open-label, prospective study that included 39 patients with chronic periprosthetic hip joint infection (hip PJI). All patients underwent appropriate surgical treatment and were divided into two groups: the study group ( n = 19), in which personalized phage therapy was used in combination with targeted antibiotic therapy, and the comparison group ( n = 20), which received antibiotic therapy alone. The median follow-up period was at least 120 weeks; the recurrence rate was assessed after 104 weeks. The primary criterion for treatment efficacy was eradication of PJI and the absence of PJI recurrence within 104 weeks after revision arthroplasty. Results The odds of PJI recurrence within 104 weeks of follow-up in the study group were five times lower than in the comparison group ( OR = 0.2), with recurrence rates of 10.5 % and 45.0 %, respectively ( p = 0.031). The study group demonstrated significantly higher implant survival compared with the comparison group: implant survival at 104 weeks reached 89 % and 55 %, respectively. The mean risk ratio for implant loss in the David Cox proportional hazards model was 0.17 (log-rank test, p = 0.012). The study group also showed a significantly higher proportion of recovered patients compared with the comparison group, with rates of 89.5 % and 55.0 %, respectively ( OR = 6.3; p = 0.031). Discussion The results obtained for the causative PJI agents are consistent with the data in the literature. Both groups were dominated by cefoxime-resistant forms of staphylococci as a marker antibiotic, which reflects the PJI patterns of development in arthroplasty. The use of antibacterial drugs in large doses for eradication of pathogenic bacteria in biofilms leads to the accumulation of mutations in the genomes of the causative PJI agents, which is the reason for the development of drug resistance and recurrence of infection. The use of alternative therapies for PJI, in particular phage therapy, may change the treatment strategy. Adjuvant phage therapy has potential in the PJI caused by antibiotic-resistant pathogens. Conclusion Adjuvant phage therapy combined with antibiotic therapy is an effective treatment modality for periprosthetic hip joint infection caused by multidrug-resistant pathogens and may significantly reduce the recurrence rate of periprosthetic infection and thereby improve clinical outcomes. Further large randomized studies are required to confirm our findings and to use this method.